CorMedix reports Q4 2023 net loss $14.8M; FDA approved DefenCath; launch April 2024

CorMedix Inc.

Net loss Q4 2023 $14.8M ($0.26/sh) vs $8.2M ($0.20/sh) Q4 2022; operating expenses $15.7M.
Full year 2023 net loss $46.3M ($0.91/sh) vs $29.7M ($0.74/sh) in 2022.
FDA approved DefenCath Nov 15, 2023; commercial launch in inpatient setting planned April 15, 2024.
CMS TDAPA application under review; targeting July 1, 2024 outpatient launch.
Cash and short-term investments $76.0M at Dec 31, 2023; sufficient for at least 12 months.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CorMedix Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $46.3 million, or $0.91 per share, EPS $0.91 per share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: $46.3 million, or $0.91 per share
EPS: $0.91 per share
Result: reported results

Exact text from the filing

For the fourth quarter of 2023, CorMedix recorded a net loss of $14.8 million, or $0.26 per share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CorMedix Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income $46.3 million, or $0.91 per share, EPS $0.91 per share.

Period: the fourth quarter and full year ended December 31, 2023
Net income: $46.3 million, or $0.91 per share
EPS: $0.91 per share
Result: reported results

Exact text from the filing

For the year ended December 31, 2023, CorMedix recorded a net loss of $46.3 million, or $0.91 per share

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-021573

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.